Independent Factors Predict Supranormal CA 15-3 Serum Levels in Advanced Breast Cancer Patients at First Disease Relapse

Tampellini, Marco; Berruti, Alfredo; Gorzegno, G.; Bitossi, Raffaella; Bottini, Alberto; Durando, Antonio; Matteis, A. De; Farris, A.; Donadio, Michela; Fabiani, Elisabetta; Manzin, E; Arese, Paolo; Sarobba, Maria Giuseppa; Castiglione, F.; Moro, G.; Bonazzi, G; Nuzzo, Francesco; Massobrio, M; Dogliotti, Luigi

doi:10.1159/000050639

Cited by 16 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of the increase in CA 15-3 and CEA levels according to breast cancer molecular subtype may be useful in clinical practice. As regards the correlation between marker levels and metastatic site(s), the results thus far have been conflicting: Tampellini et al (16) reported that increased CA 15-3 levels were found more frequently in patients with liver metastases and in those with pleural effusion. Yerushalmi et al (20) did not identify significant differences in CA 15-3 and CEA levels between different sites of metastasis, whereas al-Jarallah et al (21) reported that the highest proportions of elevated CA 15-3 levels were found in patients with bone metastases and the highest proportions of elevated CEA levels in patients with lung, bone or liver metastases.…”

Section: Discussionmentioning

confidence: 99%

Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer

Geng

Liang

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The objective of this study was to investigate the association of serum cancer antigen and carcinoembryonic antigen (CEA) levels with clinicopathological parameters in patients diagnosed with metastatic breast cancer (MBC). We retrospectively evaluated the medical records of 284 patients diagnosed with MBC between January, 2007 and December, 2012 who fulfilled the specified criteria and the association between the levels of the two tumor marker and clinicopathological parameters was analyzed. Of the 284 patients, elevated CA 15-3 and CEA levels at initial diagnosis of recurrence were identified in 163 (57.4%) and 97 (34.2%) patients, respectively. Elevated CA 15-3 and CEA levels were significantly associated with breast cancer molecular subtypes (P<0.001 and P=0.032, respectively). Cases with luminal subtypes exhibited a higher percentage of elevated CA 15-3 and CEA levels compared to non-luminal subtypes. Elevated CA 15-3 level was correlated with bone metastasis (P=0.017). However, elevation of CEA was observed regardless of the site of metastasis. Elevation of CA 15-3 was significantly more common in MBC with multiple metastatic sites compared to MBC with a single metastasis (P=0.001). However, the incidence of elevated CEA levels did not differ between patients with a single and those with multiple metastatic sites. In conclusion, elevated CA 15-3 and CEA levels at initial diagnosis of recurrence were found to be associated with breast cancer molecular subtypes, whereas an elevated CA 15-3 level was significantly correlated with bone metastasis and an elevated CEA level was observed regardless of metastatic site. The proportion of MBC cases with elevated CA 15-3 levels differed according to the number of metastatic sites.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer

Geng

Liang

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…To our knowledge, the prognostic significance of an elevated CA15.3 and CEA in patients presenting with bone metastases has not been previously described. Several authors have commented on the correlation between overall tumour burden and CA15.3 levels (O'Hanlon et al, 1995;Tampellini et al, 2001). It is likely that elevated tumour markers reflect tumour burden in patients presenting with bone metastases.…”

Section: Discussionmentioning

confidence: 99%

Bone metastases from breast carcinoma: histopathological – radiological correlations and prognostic features

et al. 2003

View full text Add to dashboard Cite

The aim of this study was to identify factors that may be associated with the development of bone metastases in patients with metastatic breast carcinoma and to see if any of these factors had a bearing on subsequent survival. In total, 492 patients presented to the Nottingham City Hospital with metastatic breast carcinoma between July 1997 and December 2001. Of these, 267 patients had bone metastases at presentation with metastatic disease, 91 patients in this group had bone as their only site of metastatic disease. Sites of first presentation of metastatic disease were prospectively recorded, as were histological features of the primary tumour (tumour type, histological grade, lymph node stage, tumour size and oestrogen receptor (ER) status). The radiological features of the bone metastases, the metastasis-free interval and serological tumour marker levels at presentation with metastases were all recorded. There was a significant association between the development of bone metastases and lower grade tumours (P ¼ 0.019), ER-positive tumours (Po0.0001) and the lymph node stage of the primary tumour (P ¼ 0.047). A multivariate analysis found that metastasis-free interval, additional sites of metastatic disease other than bone, ER status and serological tumour marker levels all independently contributed to survival from time of presentation with bone metastases. British Journal of Cancer (2003) The survival of patients with metastases is variable ranging from a matter of months to many years. The ability to predict prognosis and response to treatment has a considerable impact on patient management. It is well established that oestrogen receptor (ER) status and site of presentation of metastatic disease have the greatest impact on patient survival, with additional contributions made by patient age, disease-free interval and histological grade.Bone is the most common site of metastases in patients with breast carcinoma and so patients with bone metastases make up the largest single group of patients presenting with metastatic disease. It has previously been reported that 20% of patients with bone metastases survive for more than 5 years, which emphasises the wide variation in survival seen in this group of patients (Coleman et al, 1987). The aim of this study was to identify factors that may be associated with the development of bone metastases and to see if any of these factors had any bearing on subsequent survival.We have assessed traditional factors such as ER status, histological grade, lymph node stage and size of the primary tumour, patient age, metastasis-free interval and the presence of metastases at sites other than bone. We have examined the radiological appearance of the bone metastases and looked for associations with the histological features of the tumour and patient survival. In common with other centres, we increasingly use serological tumour markers in the diagnosis and monitoring of patients with metastatic breast carcinoma. The prognostic significance of elevated tumour markers at presentation ...

show abstract

“…An increase in CA15-3 level is most commonly observed in hormone receptor positive breast cancer (HR?) whereas the incidence of CA15-3 elevation is lowest in the HER2-enriched type of disease [15][16][17]. In addition, elevation of CA15-3 proved more common and pronounced in breast cancer with three or more metastatic sites, when compared to breast cancer with single metastasis and in patients with pleural metastasis at the time of diagnosis.…”

Section: Breast Cancermentioning

confidence: 96%

Serum tumor markers and PET/CT imaging for tumor recurrence detection

et al. 2012

View full text Add to dashboard Cite

When confronted with a suspicious rise in CA 15.3 in asymptomatic breast cancer patients following primary treatment and negative or equivocal conventional imaging findings, FDG PET/CT allows assessment of the site and extent of the recurring disease with an accuracy of 83 %. Both FDG PET and FDG PET/CT are superior when compared to CT alone for the purpose of recurrence detection in patients suffering from ovarian carcinoma who have completed primary therapy but demonstrate a rising serum CA-125 level. As the global accuracy of CT alone for detection of recurrence of ovarian cancer approximates 80 %, CT scan should be performed upfront to identify the site of recurrence. When confronted with negative or equivocal CT findings, FDG PET alone or FDG PET/CT should be added. In patients with rising erum CEA levels that have undergone primary treatment for a colorectal carcinoma, both FDG PET and FDG PET/ CTs allow detection of tumor recurrence with an accuracy of 95 %, well above that of CT and MRI. Available studies further suggest that FDG/PET findings will affect treatment management in 28-50 % of these patients. The detection rate of both 11C-choline and 18F-choline PET and PET/CT for local, regional, and distant recurrence in prostate carcinoma patients with a biochemical recurrence increases with rising PSA value at the time of imaging and reaches about 75 % in patients with PSA [3 ng/mL. Furthermore, PET and PET/CT with [11C]-and [18F]-choline derivates may be helpful in the clinical setting for optimization of individualized treatment.

show abstract

Independent Factors Predict Supranormal CA 15-3 Serum Levels in Advanced Breast Cancer Patients at First Disease Relapse

Cited by 16 publications

References 31 publications

Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer

Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer

Bone metastases from breast carcinoma: histopathological – radiological correlations and prognostic features

Serum tumor markers and PET/CT imaging for tumor recurrence detection

Contact Info

Product

Resources

About